摘要
目的 探讨人参牛肝菌纳米制剂对高脂饮食诱导的脂肪肝及酒精性肝炎大鼠模型的保护作用。方法 通过高脂饮食构建脂肪肝模型，持续喂养10周；通过含酒精液体饲料构建酒精性肝炎模型，持续喂养8周。将模型大鼠随机分为模型组和给药组，同时设正常对照组。干预结束后，检测大鼠肝组织形态、体质量、肝指数，以及血清ALT、AST、TC、TG、ALB、TBIL水平和炎症因子TNF-α、IL-6表达，采用JMP 16.0进行统计学分析。结果 肝组织形态显示，脂肪肝模型组肝脏体积增大、质地脆、表面脂滴分布，给药后肝小叶结构完整、色泽红润；酒精性肝炎模型组肝脏色泽暗淡、边缘圆钝，给药后肝脏棕红色、质地柔软，均接近正常对照组。体质量和肝指数方面，脂肪肝模型组体质量与肝指数显著升高（P<0.01），给药后显著降低（P<0.01）；酒精性肝炎模型组体质量降低、肝指数增高（P<0.01），给药后体质量回升、肝指数降低（P<0.05）。血清生化指标中，模型组ALT、AST、TC、TG、TBIL升高，ALB降低（P<0.01），给药后上述指标均显著改善（P<0.05或P<0.01）。炎症因子TNF-α和IL-6在模型组显著升高（P<0.01），给药后显著降低（P<0.01）。结论 人参牛肝菌纳米制剂可通过改善肝组织病理形态、调节代谢指标及抑制炎症反应，有效缓解脂肪肝和酒精性肝炎大鼠的肝损伤，具有潜在的实际应用价值。
关键词： 人参牛肝菌；纳米制剂；脂肪肝；酒精性肝炎
Abstract
Objective To investigate the protective effect of ginseng boletus edulis nanopreparation on high-fat diet-induced fatty liver and alcoholic hepatitis rat models. Methods Fatty liver model was established by high-fat diet for 10 weeks, and alcoholic hepatitis model was established by alcohol-containing liquid feed for 8 weeks. Model rats were randomly divided into model group and administration group, with a normal control group set up. After intervention, liver tissue morphology, body weight, liver index, serum levels of ALT, AST, TC, TG, ALB, TBIL, and expression of inflammatory factors TNF-α and IL-6 were detected. JMP 16.0 was used for statistical analysis. Results Liver tissue morphology showed that in the fatty liver model group, liver volume increased, texture was brittle, and surface lipid droplets were distributed; after administration, hepatic lobule structure was intact and color was ruddy. In the alcoholic hepatitis model group, liver color was dim and edges were blunt; after administration, liver was brownish-red, texture was soft, both approaching the normal control group. Regarding body weight and liver index, in the fatty liver model group, body weight and liver index significantly increased (P<0.01), and decreased significantly after administration (P<0.01); in the alcoholic hepatitis model group, body weight decreased and liver index increased (P<0.01), body weight recovered and liver index decreased after administration (P<0.05). In serum biochemical indicators, model group showed increased ALT, AST, TC, TG, TBIL and decreased ALB (P<0.01), and these indicators were significantly improved after administration (P<0.05 or P<0.01). Inflammatory factors TNF-α and IL-6 were significantly increased in the model group (P<0.01) and significantly decreased after administration (P<0.01). Conclusion Ginseng boletus edulis nanopreparation can effectively alleviate liver injury in fatty liver and alcoholic hepatitis rats by improving liver tissue pathological morphology, regulating metabolic indicators, and inhibiting inflammatory response, showing potential practical application value.
Key words： Ginseng Boletus Edulis; Nanopreparation; Fatty liver; Alcoholic hepatitis
参考文献 References
[1] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2019, 69(6): 2672-2682.
[2] Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China[J]. Gastroenterology, 2023, 165(4): 1025-1040.
[3] Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets[J]. Gastroenterology, 2011, 141(5): 1572-1585.
[4] Li X, Liu J, Zuo T, et al. Advances and challenges in ginseng research from 2011 to 2020: the phytochemistry, quality control, metabolism, and biosynthesis[J]. Natural Product Reports, 2022, 39(4): 875-909.
[5] Liu Q, Sun L, Ding Y, et al. Chemical composition, health benefits, food processing effects and applications of Boletus: A review[J]. Critical Reviews in Food Science and Nutrition, 2024, 64(29): 10812-10834.
[6] Singh AR, Desu PK, Nakkala RK, et al. Nanotechnology-based approaches applied to nutraceuticals[J]. Drug delivery and translational research, 2022, 12(3): 485-499.
[7] Subramanian P. Lipid-based nanocarrier system for the effective delivery of nutraceuticals[J]. Molecules, 2021, 26(18): 5510.
[8] Liu F L, Zhang N, Wei M, et al. A systematic review of the nano-technology applied in traditional Chinese medicines[J]. Tradit Med Res, 2025, 10(11): 68.
[9] Xiao P, Ye Z, Li X, et al. Ginseng and its functional components in non-alcoholic fatty liver disease: therapeutic effects and multi-target pharmacological mechanisms[J]. Frontiers in Pharmacology, 2025, 16: 1540255.3
[10] Chang S N, Park J G, Kang S C. Therapeutic propensity of ginsenosides Rg1 and Rg3 in rhabdomyolysis-induced acute kidney injury and renohepatic crosstalk in rats[J]. International Immunopharmacology, 2023, 115: 109602.
[11] Liu H, Liu M, Jin Z, et al. Ginsenoside Rg2 inhibits adipogenesis in 3T3-L1 preadipocytes and suppresses obesity in high-fat-diet-induced obese mice through the AMPK pathway[J]. Food & Function, 2019, 10(6): 3603-3614.
[12] Bian XB, Yu PC, Yang XH, et al. The effect of ginsenosides on liver injury in preclinical studies: A systematic review and meta-analysis[J]. Frontiers in Pharmacology, 2023, 14: 1184774.
[13] Zhou H, Liu Y, Su Y, et al. Ginsenoside Rg1 attenuates lipopolysaccharide-induced chronic liver damage by activating Nrf2 signaling and inhibiting inflammasomes in hepatic cells[J]. Journal of Ethnopharmacology, 2024, 324: 117794.
[14] Zhang M, Chang G, Sheng J, et al. Integration of metabolomics and gut microbiome to analyse the protective effect of Boletus aereus polysaccharide against LPS-induced colitis[J]. Food Science and Human Wellness, 2025.
[15] Zhang L, Meng B, Li L, et al. Boletus aereus protects against acute alcohol-induced liver damage in the C57BL/6 mouse via regulating the oxidative stress-mediated NF-κB pathway[J]. Pharmaceutical Biology, 2020, 58(1): 905-914.
[16] Zhang J, Liu Y, An C, et al. Protective effect of ginsenoside CK against autoimmune hepatitis induced by concanavalin A[J]. Foods, 2023, 12(24): 4379.
[17] Zheng Y, Wang Y, Xia M, et al. The combination of nanotechnology and traditional Chinese medicine (TCM) inspires the modernization of TCM: review on nanotechnology in TCM-based drug delivery systems[J]. Drug Delivery and Translational Research, 2022, 12(6): 1306-1325.